Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: CSL Behring GmbH, Emil-von-Behring-Strasse 76, D-35041, Marburg, Germany
Respreeza 1,000 mg powder and solvent for solution for infusion.
Respreeza 4,000 mg powder and solvent for solution for infusion.
Respreeza 5,000 mg powder and solvent for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder and solvent for solution for infusion. The powder is white to off-white. The solvent is a clear and colourless solution. The reconstituted solution has an approximate osmolality of 279 mOsmol/kg and a pH of 7.0. |
Respreeza 1,000 mg powder and solvent for solution for infusion: One vial contains approximately 1,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
After reconstitution with 20 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
The total protein content is approximately 1,100 mg per vial.
Respreeza 4,000 mg powder and solvent for solution for infusion: One vial contains approximately 4,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
After reconstitution with 76 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
The total protein content is approximately 4,400 mg per vial.
Respreeza 5,000 mg powder and solvent for solution for infusion: One vial contains approximately 5,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
After reconstitution with 95 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
The total protein content is approximately 5,500 mg per vial.
* Produced from the plasma of human donors.
Excipients with known effect: Respreeza contains approximately 1.9 mg sodium per ml of reconstituted solution (81 mmol/l).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Alfa1 antitrypsin |
Human alpha1-proteinase inhibitor is understood to be the primary anti-protease in the lower respiratory tract, where it inhibits neutrophil elastase (NE). Normal healthy individuals produce sufficient alpha1-proteinase inhibitor to control the NE produced by activated neutrophils and are thus able to prevent inappropriate proteolysis of lung tissue by NE. |
| List of Excipients |
|---|
|
Powder: Sodium chloride Solvent: Water for injections |
Respreeza 1,000 mg powder and solvent for solution for infusion: Respreeza 1,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap. 20 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Respreeza 4,000 mg powder and solvent for solution for infusion: Respreeza 4,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap. 76 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Respreeza 5,000 mg powder and solvent for solution for infusion: Respreeza 5,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap. 95 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Each pack contains:
Respreeza 1,000 mg powder and solvent for solution for infusion:
One single-use powder vial.
One solvent vial of 20°ml water for injections.
One transfer set 20/20 (Mix2Vial set) for reconstitution.
Respreeza 4,000 mg powder and solvent for solution for infusion:
One single-use powder vial.
One solvent vial of 76°ml water for injections.
One transfer set 20/20 (Mix2Vial set) for reconstitution.
Respreeza 5,000 mg powder and solvent for solution for infusion:
One single-use powder vial.
One solvent vial of 95°ml water for injections.
One transfer set 20/20 (Mix2Vial set) for reconstitution.
CSL Behring GmbH, Emil-von-Behring-Strasse 76, D-35041, Marburg, Germany
EU/1/15/1006/001
EU/1/15/1006/002
EU/1/15/1006/003
Date of first authorisation: 20 August 2015
| Drug | Countries | |
|---|---|---|
| RESPREEZA | Austria, Cyprus, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, United Kingdom |
Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
